Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.

Abstract: A phosphonium compound embedded in a matrix substrate wherein the phosphonium compound is selected from a group consisting of tris (hydroxyorgano) phosphine (THP), a THP+ salt (tetrakis (hydroxyorgano) phosphonium salt) or a condensate of THP and a nitrogen containing compound. The compound may be used to reduce the number of microorganisms in industrial systems and may also be used to reduce iron carbonate or iron, lead and zinc scale deposits.

Abstract: A medicament delivery system is disclosed. The system comprises a descending formulation for delivering the medicament and an ascending formulation to protect a patient being treated with the medicament from the side effects thereof.

Abstract: The present invention relates to a novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders which contains the same as an active component. The novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof according to the present invention can beneficially be used to prevent and treat central nervous system disorders since it exhibits an equivalent biological and pharmacological activity to venlafaxine and salts thereof which are known in the field, it has very little toxicity, and, in particular, it is outstandingly soluble in water as compared with prior-art venlafaxine derivatives.

Abstract: A method for treating an inorganic slurry to preserve the slurry against bacterial contamination, including (I) providing a slurry in a substantially homogeneous phase, and then (II) adding to the slurry an effective amount of a composition containing: (a) a tetrakis(hydroxyorgano)phosphonium salt selected from the group consisting of tetrakis (hydroxymethyl) phosphonium sulphate, tetrakis (hydroxymethyl) phosphonium chloride, tetrakis (hydroxymethyl) phosphonium phosphate, tetrakis (hydroxymethyl) phosphonium nitrate and tetrakis (hydroxymethyl) phosphonium oxalate; and (b) a dispersant selected from the group consisting of (i) a phosphonated compound containing at least one tertiary nitrogen atom and (ii) a homopolymer of an unsaturated acid; and (III) preserving the slurry against bacterial contamination, whilst avoiding instantaneous heterogeneous thickening of the slurry due to the tetrakis (hydroxyorgano) phosphonium salt.

Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Abstract: An anti-stick agent that may be incorporated into an aqueous medium to assist in the prevention of soils and bodily exudates adhering to the skin. A substrate may be utilized to assist in delivering the anti-stick agent to the skin.

Abstract: A composition suitable for application to hair and/or skin comprises Phosphates Esters, such as Xylitol Phosphate Esters and other Polyol Units Phosphoric Acid Esters. This composition can be used to improve or treat skin, including scalp, conditions in cosmetic or pharmaceutical products for acne, dandruff, seborrheic dermatitis and malodor and/or can be incorporate in such formulations as a coemulsifying agent or a preservative, alone or in combination to other emulsifying or preservative agents in order to increase such activities.

Abstract: The invention generally relates to compositions and methods of their use. More specifically, the invention relates to the use of a compound in modulating erythropoiesis in a subject by mediating the activity and/or quantity of a member present in the LPA3-mediated signaling pathway, such as lysophosphatidic acid receptor subtype 3 (LPA3).

Abstract: Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.

Abstract: The present invention concerns boosting the activity of crop protection materials comprising active ingredients from the class of the phenyl-substituted cyclic ketoenols through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium salts and/or phosphonium salts and penetrants, the corresponding materials, processes for preparing them, and their use in crop protection.

Abstract: This application discloses compositions containing synthetic threitol phosphates, in particular threitol monophosphate, threitol-bis-phosphate, threitol diphosphate, and/or threitol triphosphate. The threitol phosphates are useful in treating wounds, for cosmetic applications, and for bone and periodontal regeneration.

Abstract: A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound. The second component is one of the following biocides: hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine, 2,6-dimethyl-1,3-dioxan-4-yl acetate or ortho-phenylphenol or its alkali metal or ammonium salts.

Abstract: Stabilized benzyl phosphonic acid and naphthyl phosphonic acid analog compounds are effective in inhibiting the activity of autotaxin.

Abstract: A method of treating or preventing a viral infection in a mammal by administering a compound or pharmaceutically acceptable derivative thereof that inhibits a phosphatidic acid synthesis enzyme

Abstract: A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound. The second component is cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride.

Abstract: The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof.

Abstract: A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. According to one embodiment of the invention, antimicrobial compound containing liposomes are added to water systems prone to biofouling and biofilm formation. The liposomes, being similar in composition to microbial membranes or cells, are readily incorporated into the existing biofilm. Once the antimicrobial compound containing liposomes become entrained with the biofilm matrix, the decomposition or disintegration of the liposome proceeds. Thereafter the biocidal core is released to react directly with the biofilm encased microorganisms.

Abstract: The present invention relates to compositions that may alleviate symptoms of ocular stress, as well as methods of their production, use, and storage compositions. The compositions comprise at least one ocular epithelial cell associating group and at least one hydrophilic group. In one embodiment the at least one ocular epithelial cell associating group and at least one hydrophilic group are substituents on a conjugated polyaromatic core. The compositions may be used in ophthalmic compositions and ophthalmic devices.

Abstract: A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide (preferably TTPC), alcohol (preferably isopropyl alcohol), and functional excipients for the oil and gas recovery industry. The functional excipients for the oil and gas recovery industry are a cellulose type proppant, a poloxamer wetting agent, a friction-reducing pluronic block copolymer, a drag reducing agent such as polyethylene oxide, and a flocculating agent. The OPA may be of the dialdehyde C6H4(CHO)2 form, and the Glutaraldehyde of formula C5H8O2. Both will produce an inherent bacteriostatic effect and lower surface tension and thus aids in the spread of the TTPC on the biofilm covered surface where it is readily absorbed by the negative surfaces of proteins and bacteria. It thus serves as a binding agent between the TTPC and the application surface. The foregoing constituents are combined in preferred concentrations within acceptable ranges to provide a synergistic biological chemical complementarity system.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases, and more particularly, to a pharmaceutical composition for preventing or treating neuronal damage and neurological diseases containing, as active ingredients, any one or two or more compounds selected from a group consisting of the compound of chemical formula 1, the compound of chemical formula 2, and the acceptable salts thereof. The pharmaceutical composition repairs nerve tissue damaged by herpes zoster to reduce the acute pain caused by herpes zoster, prevents postherpetic neuralgia, and enables a fundamental treatment through the recovery of nerve tissue in the postherpetic neuralgia.

Abstract: The current invention relates to a process for stabilising a phosphorus-containing compound aqueous composition, comprising the step of adding to said composition an efficient arsenic stabilizing amount of a compound selected from the group consisting of ammonia, ammonium salt, organic amino acid, peptide and polypeptide; application of the stabilized composition for treating an aqueous system optionally containing or in contact with metal sulphide scale, which method comprises adding to said system, separately or together, an efficient anti-scale amount of a stabilized aqueous composition or for treating a water system to kill or inhibit the growth of micro organisms comprising applying thereto or forming in situ an efficient inhibiting amount of the stabilized aqueous composition.

Abstract: A chemical blend that simultaneously kills bacteria and suppresses the production of hydrogen sulfide (H2S) includes both a first chemical, which may be a glutaraldehyde, a tetrakishydroxymethyl phosphonium sulfate (THPS), a quaternary amine compound, a thiocyanate, a carbamate, a cinnamaldehyde, an alkyl dimethyl benzyl ammonium chloride, and/or a diamine diacetate; a second chemical which is a quinone; optionally a third chemical, which is a phosphate compound and a solvent which includes monoethylene glycol. The chemical blend has shown synergistic results for killing bacteria and/or suppressing the production of hydrogen sulfide as compared with the addition of the results of each of the components of the blend used separately.

Abstract: The present invention is directed to the use of modulators of the mammalian target of rapamycine (mTOR) pathway, glucose and/or glucose enhancers for treating retinal disorders and, in particular, for prolonging the viability of cone cells.

Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.

Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).

Abstract: Disclosed are novel methods and compositions for treating inflammatory diseases and disorders, utilizing structural analogs of platelet activating factor (PAF).

Abstract: The invention relates to phosphoric acid esters containing A) at least one structural unit derived from substances of constituent a), the substances of constituent a) being selected from orthophosphoric acid and at least one of the derivatives thereof; B) at least one structural unit derived from substances of constituent b), the substances of constituent b) being selected from at least one compound of formula (I) R2—O—(CH2CH2O)U(C3H6O)V(DO)w—H; and C) at least one structural unit derived from substances of constituent c), the substances of constituent c) being selected from at least one polyol which has more than 2 OH groups and can also carry at least one alkoxylate group. The alkoxylate groups are respectively formed from at least one unit selected from CH2CH2O, C3H6O and C4H8O units that can respectively be arranged in a block or in a statistically distributed manner inside the alkoxylate groups.

Abstract: The invention relates to alkoxylated phosphoric acid triesters of formula (I) wherein x, y and z respectively stand for a number between 51 and 200. The alkoxylated phosphoric acid triesters of formula (I) are characterised especially by advantageous thickening properties.

Abstract: The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment.

Abstract: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.

Abstract: Biofouling may be prevented or at least mitigated by employing a cinnamaldehyde additive to augment the affect of the conventional biocide. Exemplary cinnamaldehyde additives include, but are not limited to, cinnamaldehyde, cinnamic acid and cinnamyl alcohol. A cinnamaldehyde additive by itself, in some applications, may also inhibit biofouling.

Abstract: A novel process for controlling weeds in a crop comprising sorghum, the process comprising the application of a herbicidally effective amount of: (i) mesotrione, and (ii) a second herbicide selected from one or more of prosulfuron, dicamba, 2, 4-D, halosulfuron-methyl and quinclorac to the locus of the weeds is disclosed.

Abstract: The present invention relates to compositions and methods that may be used to diagnose and treat cancer, particularly T-cell leukemia. According to one preferred embodiment of the present invention, methods are provided for determining whether reducing or blocking NOTCH-1 activation will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient, including T-cell leukemia, myeloleukemia, neuroblastoma, breast cancer, and ovarian cancer. The methods generally include determining if the patient harbors one or more mutations in a PTEN coding region. In particular, the methods may be used to determine whether reducing or blocking NOTCH-1 activation, with one or more ?-secretase inhibitors, will be effective to treat, prevent, or ameliorate the effects of a cancer in a patient.

Abstract: Provided are a drug, a cosmetic, etc. for promoting production of ceramide. Provided is a ceramide production promoter including a compound represented by the formula (1) or salts thereof as an active ingredient (in the formula, R1 represents a phosphono group or a hydrogen atom, R2 represents an alkyl group having 8 to 24 carbon atoms or an acyl group having 8 to 24 carbon atoms, and R3 represents an alkyl group having 1 to 24 carbon atoms when R1 represents a phosphono group or represents a phosphono group when R1 represents a hydrogen atom, or a salt thereof as an active ingredient.

Abstract: A method, computer-readable medium, and system for identifying compounds from chemical libraries that can be used for the therapeutic treatment of a disease or used as lead compounds in a drug development program. In particular, information from homologous proteins is used to predict, for a target protein, molecular functions that can be used to screen libraries of compounds for individual compounds that are predicted to have high binding affinities for the target protein.

Abstract: The present invention relates to new imidazole modulators of M3 muscarinic acetylcholine receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.

Abstract: The invention relates to methods and compositions for improving cognitive function by using a combination of valproic acid and analogs and derivatives thereof (“valproate”) and an acetylcholinesterase inhibitor (AChEI). In particular, it relates to the use of a combination of a valproate and an AChEI in treating age-related cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-Associated Memory Impairment (AAMI) or Age-Related Cognitive Decline (ARCD).

Abstract: The present invention relates to the use of osmolytes for treating allergic or viral respiratory diseases, e.g. allergic rhinitis (hay fever) as well as rhinovirus and/or adenovirus infections. The invention also relates to a medicament preparation containing one or more compounds from the group of osmolytes. The group of osmolytes used in the invention comprises various low-molecular substances , more specifically ectoine, 4,5,6,7-tetrahydro-2-methyl-1H-[1, 3]-diazepine-4-S-carboxylic acid (homoectoine), hydroxyectoine, di-myo-inositol-phosphate (DIP), to cyclic 2,3-diphosphoglycerate (cDPG), 1,1-diglycerol phosphate (DGP), ?-mannosylglycerate (firoin), ?-mannosylglyceramide (firoin-A), dimannosyl-diinositol phosphate (DMIP), glucosylglycerol, taurine, betaine, citrulline, and/or a derivative, e.g. an acid, salt, or ester of said compounds.

Abstract: Phosphoric esters comprise A) one or more structural units derived from substances of component a), the substances of component a) being selected from orthophosphoric acid and one or more of its derivatives, B) one or more structural units derived from substances of component b), the substances of component b) being selected from one or more compounds of formula (I) R2—O—(CH2CH2O)u(C3H6O)v(DO)w—H??(I) and C) one or more structural units derived from substances of component c), the substances of component c) being selected from one or more diols of formula (II) HO—(CH2CH2O)a(C3H6O)b(DO)c—H??(II) where the sum total a+b+c is ?1 and the phosphoric ester contains 2 or more phosphorus atoms per molecule which are bridged via a structural unit derived from the compounds of formula (II). The phosphoric esters of the invention are very useful in the manufacture of cosmetic, pharmaceutical and dermatological compositions.

Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.

Abstract: Glycerophosphate salts have been found to hasten the healing and rapid scaling of lesions of the mouth. Methods are provided for improving healing of an oral lesion or preventing diseases or conditions related to an oral lesion using a glycerophosphate salt. In particular, methods are provided for preventing diseases or conditions related to an oral lesion using calcium glycerophosphate (CGP).

Abstract: The present invention provides methods and formulations for reducing or inhibiting increase in the concentration of microbes in a water-based fluid. The methods and formulations of the present invention use glutaraldehyde and a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts, C1-C3 alkyl- and alkenyltris(hydroxymethyl)phosphonium salts and tris(hydroxymethyl)phosphine, in a ratio of hydroxymethyl-substituted phosphorus compound to glutaraldehyde in the range of about 2:1 to about 7:1, or about 3.5:1 to about 7.5:1. The methods and formulations of the present invention can be useful in treating water contaminated with aerobic or anaerobic bacteria in oilfield, natural gas field and other industrial applications.

Abstract: The subject invention thus provides a composition comprising at least one triglyceride, at least one phospholipid and at least one poly-unsaturated fatty acids (LC-PUFA); wherein at least about 1% of the LC-PUFA in the composition is conjugated to said at least one phospholipid and uses thereof.

Abstract: Method for increasing the yield in glyphosate-resistant legumes, which comprises treating the plants or the seed with a mixture comprising a) a compound of the formula I where X, m, Q, A have the meaning given in the description and b) a glyphosate derivative II in a synergistically active amount.

Abstract: This application discloses compositions containing synthetic threitol phosphates, in particular threitol monophosphate, threitol-bis-phosphate, threitol diphosphate, and/or threitol triphosphate. The threitol phosphates are useful in treating wounds, for cosmetic applications, and for bone and periodontal regeneration.

Abstract: A hygiene article having calcium sugar phosphate is provided. The calcium sugar phosphate reduces the production of Toxic Shock Syndrome Toxin-1 (TSST-1) by Staphylococcus aureus.

Abstract: There is provided a composition comprising the reaction product of: (a) one or more phosphate derivatives of one or more hydroxylated actives; and (b) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.